Development of a RVFV ELISA that can distinguish infected from vaccinated animals.
BACKGROUND
Rift Valley Fever Virus is a pathogen of humans and livestock that causes significant morbidity and mortality throughout Africa and the Middle East. A vaccine that would protect animals from disease would be very beneficial to the human population because prevention of the amplification cycle in livestock would greatly reduce the risk of human infection by preventing livestock epizootics. A mutant virus, constructed through the use of reverse genetics, is protective in laboratory animal models and thus shows promise as a potential vaccine. However, the ability to distinguish infected from vaccinated animals is important for vaccine acceptance by national and international authorities, given regulations restricting movement and export of infected animals.


RESULTS
In this study, we describe the development of a simple assay that can be used to distinguish naturally infected animals from ones that have been vaccinated with a mutant virus. We describe the cloning, expression and purification of two viral proteins, and the development of side by side ELISAs using the two viral proteins.


CONCLUSIONS
A side by side ELISA can be used to differentiate infected from vaccinated animals. This assay can be done without the use of biocontainment facilities and has potential for use in both human and animal populations.
McElroy
Anita K
AK
Special Pathogens Branch, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. gsz5@cdc.gov
Albariño
César G
CG
Nichol
Stuart T
ST
D000349:Africa; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D000956:Antigens, Viral / Q000235:genetics; D003937:Diagnosis, Differential; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods*; D006801:Humans; D051379:Mice; D008877:Middle East; D011994:Recombinant Proteins / Q000235:genetics; D012295:Rift Valley Fever / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D012296:Rift Valley fever virus / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
D000914:Antibodies, Viral; D000956:Antigens, Viral; D011994:Recombinant Proteins; D014765:Viral Vaccines
Vaccine. 1986 Sep;4(3):179-84
3532605
J Med Virol. 2006 Jun;78(6):787-91
16628582
J Immunol. 1962 Nov;89:660-71
13990748
J Virol Methods. 2007 Dec;146(1-2):119-24
17645952
J Virol. 2004 Sep;78(18):9798-806
15331713
Onderstepoort J Vet Res. 2003 Mar;70(1):49-64
12825681
Vaccine. 1991 Jan;9(1):35-41
2008798
J Immunol. 1964 Aug;93:293-9
14202259
Vaccine. 1985 Jun;3(2):117-22
4036270
J Virol. 2008 Mar;82(6):2681-91
18199647
MMWR Morb Mortal Wkly Rep. 2007 Feb 2;56(4):73-6
17268404
Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):955-9
19144928
Vet Microbiol. 2008 Feb 5;127(1-2):21-8
17884306
Onderstepoort J Vet Res. 2002 Mar;69(1):95-8
12092782
Vet Microbiol. 2007 Mar 31;121(1-2):29-38
17187944
Am J Vet Res. 1997 Oct;58(10):1104-9
9328662
J Virol Methods. 2007 Mar;140(1-2):106-14
17174410
Am J Vet Res. 1987 Jul;48(7):1042-7
3631685
Vaccine. 1985 Jun;3(2):123-7
4036271
Vaccine. 1991 Oct;9(10):710-4
1759489
J Virol. 1999 Jun;73(6):5018-25
10233964
J Virol. 2006 Mar;80(6):2933-40
16501102
Clin Infect Dis. 2003 Oct 15;37(8):1084-92
14523773
Vaccine. 1999 Aug 20;18(1-2):181-9
10501248
Am J Trop Med Hyg. 1986 May;35(3):660-2
3706629
J Virol. 2000 Feb;74(3):1538-43
10627566
Prev Vet Med. 2007 Nov 15;82(1-2):72-82
17570545
Virology. 2007 Mar 15;359(2):459-65
17070883
Curr Mol Med. 2005 Dec;5(8):827-34
16375716
J Virol. 2001 Feb;75(3):1371-7
11152510